Nuo Therapeutics, Inc.: Form 10-Q for the period ended Sep 30, 2018
Filed with the SEC on Nov 16, 2018 and accepted by EDGAR at Nov 16, 2018, 17:10 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2018-09-30. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 3 months2018-07-01 to 2018-09-30 | $260.3k | us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax |
| Revenue | 9 months2018-01-01 to 2018-09-30 | $558.5k | us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax |
| Cost of revenue | 3 months2018-07-01 to 2018-09-30 | $44.9k | us-gaap:CostOfRevenue |
| Cost of revenue | 9 months2018-01-01 to 2018-09-30 | $132.1k | us-gaap:CostOfRevenue |
| Gross profit | 3 months2018-07-01 to 2018-09-30 | $215.4k | us-gaap:GrossProfit |
| Gross profit | 9 months2018-01-01 to 2018-09-30 | $426.4k | us-gaap:GrossProfit |
| Research and development | 3 months2018-07-01 to 2018-09-30 | $95.5k | us-gaap:ResearchAndDevelopmentExpense |
| Research and development | 9 months2018-01-01 to 2018-09-30 | $493.6k | us-gaap:ResearchAndDevelopmentExpense |
| Operating income | 3 months2018-07-01 to 2018-09-30 | −$411.8k | us-gaap:OperatingIncomeLoss |
| Operating income | 9 months2018-01-01 to 2018-09-30 | −$1.7m | us-gaap:OperatingIncomeLoss |
| Net income | 3 months2018-07-01 to 2018-09-30 | −$649.9k | us-gaap:NetIncomeLoss |
| Net income | 9 months2018-01-01 to 2018-09-30 | −$1.9m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months2018-07-01 to 2018-09-30 | −$0.03 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 9 months2018-01-01 to 2018-09-30 | −$0.08 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months2018-07-01 to 2018-09-30 | −$0.03 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 9 months2018-01-01 to 2018-09-30 | −$0.08 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months2018-07-01 to 2018-09-30 | 23,722,400 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 9 months2018-01-01 to 2018-09-30 | 23,128,993 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 9 months2018-01-01 to 2018-09-30 | −$1.3m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Cash and equivalents | At period end2018-09-30 | $250.2k | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2018-09-30 | $613.8k | us-gaap:AssetsCurrent |
| Total assets | At period end2018-09-30 | $759.8k | us-gaap:Assets |
| Current liabilities | At period end2018-09-30 | $1.3m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2018-09-30 | $1.3m | us-gaap:Liabilities |
| Shareholders' equity | At period end2018-09-30 | −$581.8k | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001437749-18-021015. Last ingested by Listed: Nov 14, 2026, 23:44 ET. Listed shows no prices and gives no investment advice.